Breaking News

Ajinomoto Althea Names CEO

By Kristin Brooks | January 6, 2014

Enloe to lead strategic growth efforts

J. David Enloe, Jr. has been appointed president and chief executive officer of Ajinomoto Althea Inc. Mr. Enloe will be responsible for developing strategies to support the company's growth efforts.
Mr. Enloe has more than 20 years of executive management experience, primarily in biotechnology, drug development, and GMP manufacturing. Most recently, he served as head of the Viral Therapeutics Business Unit at Lonza AG, which provides process development, scale-up and GMP manufacture of viral-based biologics. He was also the founder and chief executive officer of Vivante GMP Solutions, which he sold to Lonza in 2010. Prior to this, he was president and chief executive officer of Introgen Therapeutics.
"We are delighted to welcome David as the new leader of Ajinomoto Althea's management team," said Dr. Hiroshi Shiragami, co-chair of Ajinomoto Althea. "His unique depth of experience in the biotechnology industry, leadership abilities, financial management, manufacturing and contractual negotiation skills will be instrumental in supporting further expansion of our business."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important